President Donald Trump announced plans to impose significant import tariffs on generic medicines entering the U.S. to encourage domestic production.
This policy shift targets the global pharmaceutical supply chain, potentially increasing the cost of affordable medications while pressuring foreign manufacturers to build facilities within the United States. The move is expected to have a substantial impact on India's pharmaceutical export sector, which serves as a primary provider of generic drugs to the American market.
According to the proposal, generic drugs entering the U.S. will maintain a zero percent tariff until Aug. 1, 2028 [2], [3]. Following this period, import duties on these medicines are scheduled to rise to 100% in August 2028 [1], [3]. The tariffs are projected to increase further to 200% one year later [1], [3].
Trump said the measure is intended to protect U.S. domestic drug manufacturers. By making imports more expensive, the administration aims to incentivize the on-shoring of generic drug production [4], [1].
Reports indicate that Trump is threatening these large tariffs specifically on generic drugs that are not manufactured within the United States [4]. The phased approach provides a multi-year window before the first major duty takes effect, though the scale of the eventual tariffs remains high.
Industry analysts said the move could disrupt the flow of low-cost medications. Because India is a leading exporter of generics, the 100% [1] and 200% [1] duties could force a restructuring of how these medicines are sourced and distributed to U.S. patients.
“Tariffs on imported generics would rise to 100% in August 2028 and 200% a year later.”
This policy represents a shift toward pharmaceutical protectionism. By utilizing extreme tariff hikes, the U.S. government is attempting to reduce its strategic reliance on foreign drug supplies, particularly from India, to ensure national health security. However, the success of this strategy depends on whether domestic manufacturers can scale production quickly enough to prevent drug shortages or price spikes for consumers once the zero-percent tariff window closes in 2028.
